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Hepatitis C virus (HCV) infection is a major contributor to the development of end-stage liver disease, including cirrhosis and hepatocellular
carcinoma (HCC). We have previously shown that HCV core protein promotes immortalization of primary human hepatocytes. To identify
molecular changes involved in core protein-mediated immortalization, we have investigated differential gene expression by microarray analyses in
primary human hepatocytes and HCV core gene introduced hepatocytes after senescence (early passage), immortalization (middle passage), and
anchor-independent growth (late passage). Out of 33,000 human genes screened, 1918 transcripts were differentially expressed (>2-fold) in
immortalized human hepatocytes (IHH) as compared to negative controls. Our analyses provided a molecular portrait of changes in gene
expression associated with three distinct stages of hepatocytes after introduction of HCV core gene. Many of the overall changes were involved
with important cellular pathways, including cell growth regulation, immune regulation, oxidative stress, and apoptosis. We focused on the Stat3
signaling pathway by further verifying selected genes at the protein level relevant to hepatocyte growth regulation. Our data suggested that the
introduction of HCV core protein results in an increase in expression of IL-6, gp130, leptin receptor, and Stat3. Upregulation of these genes in turn
may regulate c-myc and cyclin D1, downstream of the Stat3 signaling pathway. Identification of these modulated genes with potential roles may
help in the selection of targets for therapies against HCV-mediated liver disease progression.
© 2006 Elsevier Inc. All rights reserved.Keywords: Hepatitis C virus; Core protein; Immortalized human hepatocytes; Microarray analyses; Interleukin-6; Stat3 signaling pathwayIntroduction
HCC is one of the most common malignancies worldwide
and is associated with multiple risk factors (Bosch et al., 2003).
HCC is believed to arise from preneoplastic lesions, usually in
the background of cirrhosis (Suriawinata and Xu, 2004). The
etiological association between HCV infection and the
development of HCC has been established (Alter, 1995;
Koike et al., 2000; Saito et al., 1990); however, the molecular
mechanisms of hepatocarcinogenesis are not well understood.⁎ Corresponding author. Division of Infectious Diseases and Immunology,
Saint Louis University, 3635 Vista Avenue, FDT-8N, St. Louis, MO 63110,
USA. Fax: +1 314 771 3816.
E-mail address: rayr@slu.edu (R. Ray).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.02.023HCV core protein has been detected in various subcellular
compartments, including cytosol, lipid droplets, endoplasmic
reticulum/Golgi apparatus, mitochondria, and nuclei (Lai and
Ware, 2000). This broad intracellular distribution raises the
possibility that core protein may modulate multiple cellular
processes. In vitro studies have shown that HCV core protein
transcriptionally regulates cellular promoters, and plays an
inhibitory role against apoptosis under certain conditions (Ray
and Ray, 2001; Bergqvist and Rice, 2001; Lai and Ware, 2000).
Expression of core protein leads to the development of
progressive hepatic steatosis, and HCC in transgenic mice
(Moriya et al., 1997, 1998). Hepatic steatosis occurs at a high
rate in chronic hepatitis C patients, and a close relationship
between steatosis and intrahepatic core protein expression has
been noted (Fujie et al., 1999). Overproduction and release of
348 A. Basu et al. / Virology 349 (2006) 347–358HCV nucleocapsid into the blood stream, and an accumulation
of core protein in the liver of infected chimpanzees in the acute
phase of infection have been suggested (Maillard et al., 2001).
We have observed that HCV core protein promotes the
immortalization of primary human hepatocytes, a natural host
for virus replication and tropism (Ray et al., 2000). IHH
displayed a weak level of core protein expression and
continuous growth for more than 5 years. Telomerase activity,
a characteristic of transformed cells, was observed in HCV core-
transfected hepatocytes after senescence. Expression of anti-
sense core gene in IHH induced cell death (Basu et al., 2002).
These results suggested that the hepatocytes, during the early
stage of immortalization, require core protein for survival.
Anchorage-independent growth of IHH provided further
evidence for a transformed phenotype at later passage levels.
Although immortalization of primary human hepatocytes
(Ray et al., 2000) or direct induction of HCC in transgenic mice
(Moriya et al., 1998) by HCV core protein have been
demonstrated, the molecular mechanism of HCV core protein-
induced hepatocyte growth regulation remains unknown.
Analysis of hepatocyte populations from HCV-infected
patients, at various stages en route to malignancy, would be
the direct approach to understand the cellular and molecular
processes of HCV-mediated HCC. However, primary cultures
of HCV-infected hepatocytes from liver at various neoplastic
stages are difficult to establish, and no cell lines at the
intermediate stages of neoplastic transformation are available
for mechanistic studies. Therefore, HCV core-transfected
primary human hepatocytes at different stages, en route to
immortalization and transformation, were used as a model to
gain insight into modulation of candidate genes or novel
pathways by DNA microarray analysis. Our results suggested
modulation of a number of cellular genes with apoptosis/cell
growth regulation, cytokine expression, and a variety of other
cellular pathways.
Results
Altered gene expression following introduction of HCV core
into primary human hepatocytes
The goal of our study was to identify changes in gene
expression of primary human hepatocytes associated withTable 1
Detailed profile analysis by clustering of genes from microarray
Cluster no. Functions involved No. of
genes
Upregulated
Early Midd
1 Apoptosis 44 14 (31.8%) 18 (4
2 Oxidative stress 6 1 (16.7%) 1 (1
3 Lipid metabolism 19 5 (26.3%) 4 (2
4 Signal transduction 202 87 (43.1%) 83 (4
5 Protein kinase cascade 25 9 (36%) 7 (2
6 Oncogenesis 17 5 (29.4%) 5 (2
7 Cell cycle 65 30 (46%) 35 (5
8 Immune regulation 54 27 (50%) 20 (3
9 Cytokine response 12 7 (58.3%) 5 (4different stages post immortalization by HCV core protein. We
have utilized the Human 133 Plus 2.0 expression GeneChip
microarray from Affymetrix containing 33,000 well-substanti-
ated human genes. Data from microarray were analyzed and
compared with primary human hepatocytes by Affymetrix
software, and filtered using the Affymetrix Data Mining tool.
Approximately 1918 genes were differentially expressed in core
introduced hepatocytes as compared to primary human
hepatocytes. A complete list of the genes with symbol, probe
set ID, accession number, and functional description are
provided as Supplementary Table 1. Of these, 736, 749, and
770 genes were upregulated (>2-fold) in the early, middle, and
late passage hepatocytes, respectively. Genes whose expression
were downregulated (>2-fold) following core protein expres-
sion represented 575, 606, and 522 in the early, middle, and late
passage hepatocytes. A detailed profile analysis led us to group
the genes into 9 clusters based upon their functions (Table 1).
Genes were clustered using Spotfire software and a heat map
with two-dimensional hierarchical clustering. The map illus-
trates a gradual change in gene expression between normal
human hepatocytes and IHH (Fig. 1). Many of the overall
changes were involved with important cellular pathways,
including cytokine responsive genes, apoptosis, oncogenes,
protein kinase cascade, lipid metabolism related genes,
oxidative stress related genes, and immunomodulatory genes
(Supplementary Tables 2–8). A detailed analysis of all genes
exhibiting changes in expression is beyond the scope of the
current report. We particularly focused on selected genes
relevant to hepatocyte growth regulation, stress response, and
cytokine modulation to further understand HCV core protein
mediated functions.
HCV core protein activates Stat3 in human hepatocytes
Signal transducers and activators of transcription (Stat)
family proteins function as the downstream effectors of cytokine
signaling, and play a critical role in cell growth regulation.
Among these, Stat3 is often constitutively activated in many
cancers, including those involving the liver. This activation has
been associated with proliferation and antiapoptotic responses
(Bowman et al., 2000). Stat3 is activated by multiple cytokines,
including IL-6, LIF, and OSM, using the gp130 receptor. Our
microarray analyses suggested an upregulation of IL-6 and otherDownregulated
le Late Early Middle Late
0.9%) 10 (22.7%) 9 (20.5%) 11 (25%) 22 (50%)
6.7%) 0 (0%) 5 (83.3%) 5 (83.3%) 5 (83.3%)
1%) 5 (26.3%) 8 (42.1%) 12 (63.15%) 12 (63.15%)
1.1%) 83 (41.1) 61 (30.2%) 66 (32.67%) 44 (21.78%)
8%) 8 (32%) 9 (36%) 8 (32%) 9 (36%)
9.4%) 6 (35.2%) 6 (35.29%) 4 (23.53%) 4 (23.53%)
3.8%) 30 (46%) 13 (20%) 9 (13.84%) 9 (13.84%)
7%) 16 (29.6%) 16 (29.63%) 16 (29.63%) 16 (29.63%)
1.6%) 4 (33.3%) 4 (33.33%) 2 (16.66%) 3 (25%)
Fig. 1. Hierarchical clustering of altered gene expression in HCV core-transfected hepatocytes. A heat map is shown illustrating two-dimensional hierarchical
clustering of 1918 genes identified as differentially regulated in normal versus core immortalized human hepatocytes by analysis of variance at a 95% confidence level.
Genes increased or decreased during HCV core protein expression cluster separately (shown on left). Increase and decrease expressions of specific genes are illustrated
by red and green, respectively, while black indicates no change.
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differentiation into Ig-secreting cells and aids in the induction of
inflammatory response. A significant elevation of serum IL-6 in
chronically infected HCV patients may represent a virus-
induced inflammatory state (Malaguarnera et al., 1997). We
analyzed the levels of IL-2, IL-4, IL-6, IL-10, IFN-γ, and TNF-α
secreted from IHH or normal hepatocyte culture to verify the
data obtained by microarray. The levels of human cytokines
were determined by BD Cytometric Bead Array Human Th1/
Th2 Cytokine Kit II (BD Biosciences, San Diego, CA).
Recombinant standards are provided in the kit for generation
of standard curves. We calculated that the primary hepatocytes
secrete 404–450 pg/ml of IL-6 in the medium from comparison
with the standard curve. The IHH at different stages of
immortalization secreted 1144–1397 pg/ml of IL-6 in the
medium. Therefore, our results suggested that IL-6 secreted
from IHHwas enhanced by approximately 3-fold as compared to
primary hepatocyte culture (Fig. 2A). The increased secretion of
IL-6 by IHH correlated with an increase in gp130 expression,
and subsequent signaling pathway. The transmembrane protein
gp130 plays a central role in cytokine action as a signaltransducing receptor subunit common to all IL-6 type cytokines.
Western blot analysis suggested an ∼4-fold increase in
expression of gp130 in IHH (Fig. 2B). Leptin, an adipocyte
hormone, regulates reproduction, hematopoiesis, and immune
functions. Leptin stimulation activates the JAK-STAT signaling
pathway by tyrosine phosphorylation, and translocation of
activated Stat3 from the cytoplasm to the nucleus (Sanchez-
Margalet and Martin-Romero, 2001). Leptin has been implicat-
ed in the pathogenesis of obesity, steatosis, and fibrosis
progression in chronically infected HCV patients (Patel et al.,
2003). Leptin has direct action on liver fibrogenesis mediated by
the JAK/STAT pathway via the leptin receptor (LEPR). Leptin
also induces oxidative stress via activated JAK (Cao et al.,
2004). An increase in LEPR and the highly homologous leptin
receptor gene-related protein (LEPROTL1/OB-RGRP) were
observed in the microarray. The LEPR and LEPROTL1/OB-
RGRP have been shown to trigger cellular signaling pathways.
The expression of LEPR was further verified at the protein level
(Fig. 2C). Western blot results suggested an ∼4–6-fold increase
in the LEPR level, implicating that Stat3 could be modulated by
different cytokine pathways.
Fig. 2. HCV core protein upregulates IL-6 and hepatocyte growth regulatory proteins. Cytometric bead array for IL-6 secretion by normal hepatocytes and IHH at three
different passage levels (A). Western blot analysis using specific antibodies for detection of gp130 (B), LEPR (C), Stat3 and phosphor-Stat3 (D), c-myc (E), and cyclin
D1 (F), in primary and at different passage levels of IHH. Cellular actin was used as an internal control to verify the level of protein load in each lane. The positions of
the specific proteins were also verified from molecular weights using prestained molecular weight markers.
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activated in all three stages of core associated immortalization
of human hepatocytes examined in this study. We next verified
whether core protein enhances the endogenous Stat3 expression
at the protein level in IHH. For this, cell lysates were analyzed
by Western blot using specific antibodies. Late passage IHH
expressed ∼4.5-fold higher Stat3, and an increase of its
activated phosphorylated form as compared to control primary
human hepatocytes (Fig. 2D). The level of c-myc was also
upregulated in all three passage levels of IHH (Fig. 2E). c-myc
is a downstream molecule of the Stat3 pathway. c-myc protein
expression was more than 3-fold higher than that seen in normal
hepatocytes at three different passage levels of IHH. Cyclin
D1 increases cell cycle at G1 phase, and is located within the
down-stream signaling pathway of Stat3. We examined cyclin
D1 expression at protein level by Western blot analysis
(Fig. 2F). Our results suggested an ∼2-fold increase in cyclin
D1 expression in IHH, as compared to control hepatocytes.Fig. 3. Hierarchical clustering of apoptosis related genes in HCV core introduced hu
clustering of 44 genes identified as differentially regulated in normal versus core imm
increased or decreased during HCV core protein expression cluster separately (shown
and green, respectively, while black indicates no change. (For interpretation of the ref
this article.)Together, these results suggested that HCV core protein
upregulates Stat3 signaling pathway in hepatocytes, which in
turn enhances cell growth.
Modulation of signaling molecules for apoptosis
A total of 44 genes involved in the apoptotic process were
differentially expressed in IHH. A heat map with two-
dimensional hierarchical clustering showing a difference in
gene expression between primary human hepatocytes and IHH at
different stages is shown (Fig. 3). The early and middle passage
IHH displayed similar changes and formed their own distinct
cluster, which was different from the changes in late passage
hepatocytes. After introduction of the core gene, microarray data
indicated that Bcl family-related gene expression was upregu-
lated. A member of the Bcl-2 family, Bcl-xL, and a related gene
BNIP3L were upregulated in late passage hepatocytes. Increased
levels of Bcl-xL are detected in human cancers, includingman hepatocytes. A heat map is shown illustrating two-dimensional hierarchical
ortalized hepatocytes by analysis of variance at a 95% confidence level. Genes
on left). Increase and decrease expressions of specific genes are illustrated by red
erences to colour in this figure legend, the reader is referred to the web version of
352 A. Basu et al. / Virology 349 (2006) 347–358hepatocellular carcinoma (Watanabe et al., 2002; Gobe et al.,
2002). Increased Bcl-xL could result from a mutation in the
regulatory element of the Bcl-xL gene or from a component of
regulatory pathways that control either the transcription or the
stability of Bcl-xL mRNA. The antiapoptotic activity of Bcl-xL
(Borner, 2003) may facilitate transformation of primary human
hepatocytes into IHH. Thus, an upregulation of members of the
Bcl-2 family of genes indicated that an antiapoptotic mechanism
is induced in IHH.
Changes in gene profile associated with lipid metabolism and
stress response
We have observed that many lipid metabolism and stress
response-related genes are expressed differentially in IHH as
compared to primary hepatocytes (Fig. 4). Recently, much
attention has been drawn to metabolic disorders in HCV
infection (Koike and Moriya, 2005). Initially, hepatic steatosis
and disturbances in lipid metabolism were found to be
characteristic of HCV infection, and subsequently a correlation
was noted between HCV infection and diabetes. HCV coreFig. 4. Hierarchical clustering of genes related to altered lipid metabolism in IHH. A h
left) of 19 differentially regulated genes at different passage levels of IHH. Increas
respectively, while black indicates no change. (For interpretation of the references to cprotein has been suggested to induce insulin resistance by itself
in a way of disturbing the intracellular signaling pathway of
insulin. Oxidative stress induced by HCV infection is also
thought to play a role in the pathogenesis of liver disease
(Erhardt et al., 2002). Among the other stress response-related
genes, the difference was highest in the late passage level of IHH
(Fig. 5A). Oxidative stress-related genes, SEPP1 and SOD2,
were downregulated in IHH. Both SEPP1 and SOD2 are
components of the antioxidant system, localized in the
mitochondria, and the levels of these proteins have been
previously shown to inversely correlate with cancer cell growth
(Weydert et al., 2003; Ahlenstiel et al., 2004).
Inducible nitric oxide synthase (iNOS) was upregulated in
the early, middle, and late passage IHH as compared to the
normal hepatocytes. Confirmatory Western blot analysis
suggested an upregulation of ∼4-fold iNOS in late passage
IHH (Fig. 5B). iNOS induces the production of total nitric oxide
(NO), i.e., NOx which includes both nitrites (NO2
−) and nitrates
(NO3
−) from L-arginine in inflamed tissues. NO plays an
important role in many physiological and pathological condi-
tions, serving as an intercellular and intracellular messenger andeat map is shown illustrating two-dimensional hierarchical clustering (shown on
e and decrease expressions of specific genes are illustrated by red and green,
olour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. (A) Hierarchical clustering of genes related to altered oxidative stress in IHH. A heat map is shown illustrating two-dimensional hierarchical clustering of 5
differentially regulated genes. Genes increased or decreased during HCV core protein expression cluster separately (shown on the left). Increase and decrease
expressions of specific genes are illustrated by red and green, respectively. (B) Western blot analysis for inducible nitric oxide synthetase (iNOS) in IHH. The iNOS
expression level in IHH at 3 different passage levels was compared with primary human hepatocytes. Cellular actin was used as an internal control to verify the level of
protein load in each lane. The specific proteins were also verified for molecular weights using prestained standard molecular weight markers. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
353A. Basu et al. / Virology 349 (2006) 347–358antimicrobial agent (Machida et al., 2004). Therefore, we
suggest that HCV core protein can stimulate the production of
NO through activation of the gene for iNOS. NO induces DNA
cleavage, and enhances the chance of mutation. This sequence
of events in the early and middle passage IHH may contribute to
HCV-mediated pathogenesis and oncogenesis.HCV core protein alters immune modulatory genes in
hepatocytes
Interferon response plays an important role in immune
regulation and is especially significant during the early stage of
viral clearance. IFN antiviral response is complex and
Fig. 6. (A)Modulation of IFN stimulated genes (ISG) in primary hepatocytes and IHH at different stages of immortalization. The gene expressions are expressed as fold
changes with respect to the primary hepatocytes along with standard deviations obtained from three different assays. (B) Hierarchical clustering of immune modulatory
genes in IHH. A heat map is shown illustrating two-dimensional hierarchical clustering of 76 differentially regulated genes. Immune modulatory genes increased or
decreased duringHCV core protein expression cluster separately (shown on the left). Increase and decrease expressions of specific genes are illustrated by red and green,
respectively, while black indicates no change. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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355A. Basu et al. / Virology 349 (2006) 347–358constitutes more than the classically defined antiviral pathways
of 2′,5′-oligoadenylate synthetase (OAS), double-stranded
RNA-dependent protein kinase R (PKR), and the MxA genes.
Indeed, numerous IFN responsive genes have been described,
and the roles of many of these in antiviral responses have yet to
be defined. Eleven of the IFN stimulated genes exhibited a
change in expression by microarray analyses (Fig. 6A; Table 2).
Among these genes, IFN-γ receptor is downregulated in core
introduced hepatocytes. The expression pattern of IFN response
genes can be divided into two distinct groups with middle and
late passage level of IHH displaying a different profile from
the early passaged IHH (Fig. 6B). Differential regulation of
IFN stimulated genes suggested that regulatory pathways
and IFN types are operative with cell passage levels. The
mechanisms regulating these different expression patterns are
not clear at this time.
Cytokines are key players in the regulation of immune
responses. In HCV infection, the production of inappropriate
cytokine levels contributes to viral persistence and affects
therapeutic response (Thimme et al., 2002). In the microarray
analyses, several cytokine–chemokine transcripts were found to
be elevated. Among the genes, BMP2 was found to be
upregulated. BMP2 belongs to the transforming growth
factor-beta (TGF-β) superfamily and plays an important role
in hepatic stellate cell activation and hepatic fibrosis (Shen et
al., 2003). We also observed upregulation of SPP1 transcription,
which often correlates with the metastatic potential of
transformed cells. SPP1 overexpression has been associated
with HBV-related HCC (Ye et al., 2003). CC-chemokine
receptor 5 (CCR5) was upregulated in the early and middle
passages of IHH, while downregulation of CCR5 was observed
in late passage IHH, which may have important consequences
for the host's immune defense. During early HCV infection,
prominent CD8+ T cell responses are observed involving
transient upregulation of CCR5 expression. On other hand, in
chronic HCV infection, CD8+ T lymphocytes show sustainedTable 2
IFN-stimulated genes
Gene title Gene
symbol
Molecular function description
Interferon regulatory factor 6 IRF6 Transcription factor activity
Interleukin 6 IL6 Cytokine activity/interleukin-6
Interferon-induced protein with
tetratricopeptide repeats 1
IFIT 1 –
Interferon-induced protein
with tetratricopeptide repeats 2
IFIT 2 –
Interferon, gamma-inducible
protein 16
IFI 16 Double-stranded DNA binding
repressor activity
Interferon-induced protein 44 IFI 44 –
Interferon stimulated gene 20 kDa ISG 20 Exonuclease activity
Interferon-induced protein
with tetratricopeptide repeats 4
IFI T4 –
Interferon, alpha-inducible protein
(clone IFI-15K)
G1P2 Protein binding receptor activi
Interferon gamma receptor 1 IFNGR1 Interferon gamma receptor act
Interferon induced transmembrane
protein 3 (1-8U)
IFITM3 –dysfunction with poor type 1 cytokine secretion in response to
HCV antigens and reduced expression of CCR5 (Ahlenstiel et
al., 2004). Decreased CCR5 expression in late passage IHH
may correspond to the diminished cytokine responses as
observed during chronic HCV infection.
Discussion
HCV gene expression that is unique to permissive natural
host cells may influence the magnitude or spectrum of core
protein activity. In this study, we have identified differentially
expressed genes associated with HCV core protein expression
in human hepatocytes by cDNA microarrays. This study
represents the first global analysis of the transcriptional
response of primary human hepatocytes following introduction
of HCV core gene. A total of 1918 genes in the array were
significantly up- or downregulated following HCV core protein
expression and assigned into 9 clusters. Several cellular gene
families with significant and distinct biological functions were
modulated in IHH. Some of these changes included genes
involved in apoptosis, cell growth regulation, oxidative stress,
and immune modulation. HCV core protein upregulated Stat3;
and activated downstream signaling molecule Bcl-xL. Further-
more, our analyses provided a molecular portrait of changes in
gene expression associated with three distinct hepatocyte stages
after introduction of HCV core gene. Recently, Miyoshi et al.
(2005) suggested that HCV core protein downregulates the
expression of suppressor of cytokine signaling (SOCS-)1 gene,
contributing to the pathogenesis in HCV infection including
hepatocarcinogenesis. The expression of SOCS-1 gene was
significantly suppressed in the liver of core gene transgenic
mice and HepG2 cells expressing the core protein. SOCS-1
expression level was decreased in HCV-positive human liver
tissues. This group of investigators also reported that the core
protein affected Stat3 activation after interleukin-6 stimulation
in mouse liver tissues and cells. Our results from the currentStatus on IHH compared to primary hepatocytes
Early passage Middle passage Late passage
Downregulated Downregulated Downregulated
receptor binding Upregulated Upregulated Upregulated
Upregulated Upregulated Upregulated
Upregulated Upregulated Upregulated
/transcriptional Upregulated Upregulated Upregulated
Upregulated Upregulated Upregulated
Upregulated Upregulated Upregulated
Upregulated Upregulated Upregulated
ty Upregulated Upregulated Upregulated
ivity Downregulated Downregulated Downregulated
Downregulated Downregulated Downregulated
356 A. Basu et al. / Virology 349 (2006) 347–358study suggesting an upregulation of Stat3 and IL-6 in HCV core
protein-induced immortalized human hepatocytes agree well
with the earlier observations (Yoshida et al., 2002; Miyoshi et
al., 2005), although we did not observe any significant
repression of SOCS-1 gene in our microarray analyses in
comparison to primary human hepatocytes. Stat activation is
associated with several tumor viruses. Epstein–Barr virus-
mediated transformation leads to uncontrolled activation of
Stats (Weber-Nordt et al., 1998). Kaposi's sarcoma-associated
herpesvirus ORF50 stimulates transcriptional activity of Stat3
(Gwack et al., 2001). Rous sarcoma virus v-src oncoprotein
phosphorylates and activates Stat3 (Yu et al., 1997; Cao et al.,
1996). Thus, Stat3 is an ideal anticancer target (Darnell, 2005)
and can be specifically inhibited by small molecules (Yu and
Jove, 2004). The therapeutic potential of Stat3 should be
explored for treatment of HCV-mediated chronic liver disease.
Transcription of several genes involved in immune
regulation (cytokine, interferon, and immune response) and
cellular physiology (apoptosis, cell growth regulation, and
oxidative stress) was modulated in IHH as a result of HCV
core protein expression. Activation of cytokine gene BMP2
was observed in all the IHH, while SPP1 was activated only in
early passage of IHH. Upregulation of interferon regulatory
gene IL-6 in IHH suggested a virus induced inflammatory state
(Malaguarnera et al., 1997), while activation of CXCL11 may
have pathogenic importance for recruitment of T cells (Helbig
et al., 2004). HCV core and NS3 proteins induce iNOS
expression and production of NO, which in turn may cause
DNA damage, resulting in enhanced mutations of cellular
genes (Machida et al., 2004). HCV-infected patients also have
higher iNOS activity (Rahman et al., 2001). CCL5, an
important gene related to oxidative stress, modulation of
hepatic inflammation, and response to interferon therapy in
chronic hepatitis C (Wang et al., 1999), was found to be
activated in IHH by microarray analyses. Our results support
these earlier observations and suggest the importance of core
protein in HCV-mediated pathogenesis. Interestingly, we have
observed modulation of a number of other genes responsible
for hepatocyte physiology. Among these, we have observed an
activation of CCNE2 in IHH, known to increase in tumor-
derived cells, and suppression of MCC, a candidate tumor
repressor (Payton et al., 2002). An antiapoptotic gene
SERPINB2, known to overexpress in carcinomas (Darnell et
al., 2005), was also found to be activated in IHH. Interestingly,
FOS gene is known to modulate plasticity of epithelial
hepatocytes and acts as a tumor suppressor in neoplastic
hepatocytes by stimulating cell cycle inhibition and cell death
(Mikula et al., 2003) was suppressed in IHH. Results from our
study also agree with the observations from Smith et al.
(2003a, 2003b) that CCNE2 and SEPP1 are activated in HCV-
related liver disease and HCC. We have also observed that
some of the important changes in gene expression of early
stage IHH have affected the transcriptional network regulated
by IFN-γ-inducible genes (CXCL10, CXCL11). In conclusion,
through analyses of host cell gene expression profiling, we
found a number of cellular genes whose expression levels are
markedly modified by HCV core protein in human hepato-cytes. Our results suggest potential roles of HCV core protein
as regulators of cell growth promotion, and may help in
identifying novel targets for therapeutic modalities against
liver disease progression.
Materials and methods
Hepatocyte culture
Primary human hepatocytes immortalized by transfection
with HCV core genomic region from genotype 1a under the
control of a CMVearly promoter in pcDNA3 expression vector
were generated as described earlier (Ray et al., 2000).
Immortalized human hepatocytes (IHH) were seeded on
collagen type I-coated plate and maintained at 37 °C in a
defined culture medium supplemented with growth factors and
antimicrobials (SAGM, Clonetics, CA). Telomerase activity, a
characteristic of transformed cells, was evident in the
transfected hepatocytes immediately after senescence. IHH
displayed a low level of HCV core protein expression, albumin
secretion, focal cytoplasmic, and membrane staining for
carcinoembryonic antigen (CEA), biliary glycoprotein (BGP1/
CEACAM1), and nonspecific cross reacting antigen (NCA/
CEACAM6). RNA extracted from IHH exhibited expression of
hepatobiliary transport marker genes, such as multi-drug
resistance-associated protein (MRP), liver-specific organic
anion transporter (LST1), and human Na+-taurocholate co-
transporting polypeptide (NTCP). IHH retained an immortal-
ized phenotype and has exhibited continuous growth for more
than 5 years. IHH between passages 10 and 15 after senescence
are referred as early passage cells. During this time, cells
required the expression of HCV core gene for their survival and
did not display anchorage-independent growth (Basu et al.,
2002). IHH between passages 28 to 33 are referred as middle
passage and displayed anchorage-independent growth forming
small colonies. The passage levels above 50 are referred as late
passage of IHH. Normal hepatocytes from the same donors or
random donors were used as controls.
RNA isolation
Total cellular RNA was extracted from IHH grown to about
50–70% confluency using TRIzol Reagent (Invitrogen, Carls-
bad, CA) following supplier's protocol. The extracted RNAwas
dissolved in RNase-free water for determining concentration
and purity from absorbance at 260 nm and 280 nm. Quality of
the RNA was also analyzed from 28S:18S ribosomal RNA by
agarose gel electrophoresis.
Microarray analysis
We utilized the Human 133 Plus 2.0 expression GeneChip
microarray (Affymetrix, Santa Clara, CA). The gene chip
contains 45,000 probe sets representing more than 39,000
transcripts derived from 33,000 well-substantiated human
genes. This set design uses sequences selected from GenBank,
dbEST, and RefSeq. Nucleic acids from hepatocytes were
357A. Basu et al. / Virology 349 (2006) 347–358hybridized to the GeneChip array to determine RNA
abundance for expression studies. The cDNA synthesis was
carried out with the Affymetrix One-Cycle cDNA synthesis
kit using a T7 Oligo-dT primer and Invitrogen's SuperScriptII
reverse transcriptase using 10 μg of purified total cellular
RNA. The cDNA was then purified with Qiagen cDNA
cleanup spin columns. The purified cDNA was in vitro
transcribed into cRNA, using the T7 Megascript kit (Invitro-
gen, CA). The resulting cRNA was biotinylated with random
hexamer primer using Superscript II (Invitrogrn, CA), purified
using Qiagen cRNA cleanup columns, and fragmented via
metal-catalyzed hydrolysis under slightly alkaline conditions.
A hybridization cocktail was made with 15 μg of the
fragmented labeled cRNA, and hybridization controls of
varying concentrations supplied by Affymetrix. The hybrid-
ization cocktails were submitted to the DNA Microarray Core
facility at the Saint Louis University Cancer Center for
hybridization and scanning by use of a standardized protocol.
The hybridization mix (200 μl) was applied to the Human 133
Plus 2.0 expression GeneChip microarray, and hybridized for
16 h at 45 °C. The microarrays were washed with stringent
and non-stringent buffers to remove any non-specific
hybridization. A streptavidin–phycoerythrin conjugate was
then applied to the chip, followed by a biotinylated
antistreptavidin antibody. Finally, streptavidin–phycoerythrin
conjugate was added for a second time for fluorescent
visualization of the oligonucleotide-cRNA hybrids. The
washing and staining were performed using the Affymetrix
Fluidics Station 450. The chips were read using a GeneChip
Scanner 3000, and the resulting raw image was converted to
signal intensities, detection calls, comparison files, signal log
ratios, and change calls. Each of these pieces of data was
generated independent of each other using algorithms from the
Affymetrix GenChip Operating Software. Statistical (Student's
t test) and self-organizing map (SOM) clustering analyses
were performed with Affymetrix Data Mining Tool software.
The data were filtered by using the criteria I, MI, D, and MD
(I, increasing; D, decreasing; M, minimally, with a change of
P < 0.002 for I, P < 0.003 for MI, P > 0.998 for D, and
P > 0.997 for MD). Genes were categorized into “up,”
“down,” or “no change” categories with respect to the six
baselines in each experiment by using the Student's t test. The
changes in gene expression relative to the baseline samples
were recorded as signal log ratios (SLR) that were converted
to relative severalfold changes (FCs) by using the calculation
2n = FC, where n equals the SLR, since the log scale used is
base 2. The resulting list was composed of 1918 genes, which
were differentially expressed in IHH versus control, and
clustered using a Spotfire software.
Western blot
Western blot analysis was performed to analyze the
expression levels of Bcl-xL, Bax, Stat3, leptin receptor, c-
myc, cyclin D1, and iNOS proteins in control and experimental
cells using specific antibodies. Briefly, an equal amount of
protein from whole cell lysates in sample buffer was separatedby SDS-PAGE. Proteins were transferred onto nitrocellulose,
incubated with specific antibody, and detected by chemilumi-
nescence (Amersham). Cellular actin was detected similarly in
the reprobed blot and used as an internal control for relative
quantitation of the proteins.
Cytometric bead array
Secreted IL-2, IL-4, IL-6, IL-10, IFN-γ, and TNF-α in the
medium of hepatocyte culture were measured using the “BD
Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine CBA
Kit II” following supplier's protocol (BD Biosciences, CA). The
kit contains six different bead populations. Each bead was
coated with specific capture antibodies for cytokines and is
analogous to an individually coated well in an ELISA plate. The
cytokine capture beads are mixed with the PE-conjugated
detection antibodies and then incubated with recombinant
standards or test samples to form sandwich complexes.
Following acquisition of sample data using the flow cytometer,
the sample results are generated in graphical and tabular format
using the BD CBA Analysis Software.
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